Last update 04 Nov 2024

Clopidogrel Bisulfate

Overview

Basic Info

SummaryClopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997. Its mechanism of action is to inhibit P2Y12 receptors, which reduces platelet activation and aggregation. This subsequently decreases the risk of blood clots and their potentially fatal consequences. Clopidogrel is indicated for treating myocardial infarction, stroke, peripheral vascular disease, coronary artery disease, and cerebrovascular disease. With its role as an antiplatelet agent, Clopidogrel proves invaluable in preventing severe complications from blood clots such as heart attacks, strokes, and even death. The drug has shown efficacy in the management and prevention of cardiovascular events, making it an essential medication in modern medicine.
Drug Type
Small molecule drug
Synonyms
clopidogrel, Clopidogrel Bisufate, Clopidogrel bisulfate (USP)
+ [31]
Mechanism
P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (17 Nov 1997),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC16H18ClNO6S2
InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N
CAS Registry120202-66-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Atherosclerosis
EU
27 Jul 2009
Atherosclerosis
IS
27 Jul 2009
Atherosclerosis
LI
27 Jul 2009
Atherosclerosis
NO
27 Jul 2009
Angina, Stable
CN
01 Jan 2000
Cerebrovascular Disorders
CN
01 Jan 2000
Myocardial Ischemia
CN
01 Jan 2000
Non-St Elevated Myocardial Infarction
CN
01 Jan 2000
Non ST segment elevation acute coronary syndrome
EU
15 Jul 1998
Non ST segment elevation acute coronary syndrome
IS
15 Jul 1998
Non ST segment elevation acute coronary syndrome
LI
15 Jul 1998
Non ST segment elevation acute coronary syndrome
NO
15 Jul 1998
Non-Q wave myocardial infarction
EU
15 Jul 1998
Non-Q wave myocardial infarction
IS
15 Jul 1998
Non-Q wave myocardial infarction
LI
15 Jul 1998
Non-Q wave myocardial infarction
NO
15 Jul 1998
ST Elevation Myocardial Infarction
EU
15 Jul 1998
ST Elevation Myocardial Infarction
IS
15 Jul 1998
ST Elevation Myocardial Infarction
LI
15 Jul 1998
ST Elevation Myocardial Infarction
NO
15 Jul 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart Defects, CongenitalPhase 3
US
01 Jan 2009
Heart Defects, CongenitalPhase 3
US
01 Jan 2009
Heart Defects, CongenitalPhase 3
BR
01 Jan 2009
Heart Defects, CongenitalPhase 3
BR
01 Jan 2009
Heart Defects, CongenitalPhase 3
FR
01 Jan 2009
Heart Defects, CongenitalPhase 3
FR
01 Jan 2009
Heart Defects, CongenitalPhase 3
DE
01 Jan 2009
Heart Defects, CongenitalPhase 3
DE
01 Jan 2009
Heart Defects, CongenitalPhase 3
HU
01 Jan 2009
Heart Defects, CongenitalPhase 3
HU
01 Jan 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
609
Coronary angiography+clopidogrel+Tenecteplase
(Pharmaco-invasive Strategy)
setaidpzpl(kcffltqnuk) = kpvjdsjxjn bvjmeelpen (xfjuicilgu, cutdfhibxn - hsivvjdfhs)
-
04 Oct 2024
Primary PCI
(Standard Primary PCI)
setaidpzpl(kcffltqnuk) = nrlmshssin bvjmeelpen (xfjuicilgu, bvrilootzl - wrjfxwkxgt)
Phase 4
111
(Wild-Type Genotype)
osudguurus(xqroltwjzw) = tlxqezarry xoixwvmvwz (frinpcvxft, mzjyexpvna - drwuhmtifh)
-
06 May 2024
(Carriers of the CES1 G143E Mutation)
osudguurus(xqroltwjzw) = uubseuxvyx xoixwvmvwz (frinpcvxft, cqyhuwxwjz - blzuxecski)
Phase 4
390
Unfractionated Heparin IV+Clopidogrel+Enoxaparin 1 mg/kg
(Full-dose Anticoagulation (FDAC))
fxmvjhxlyb(pdvpjqrwnk) = fmmojlxhhu zfnniexalp (limyxbytut, hhaqbcvfsg - wbcrjcoomd)
-
19 Jan 2024
Unfractionated heparin SC+clopidogrel+Enoxaparin 40 mg SC
(Standard-dose Prophylactic Anticoagulation (SDPAC))
fxmvjhxlyb(pdvpjqrwnk) = monbdmztqs zfnniexalp (limyxbytut, gkuzxiilop - gdmuwnwsai)
Phase 4
61
(Diabetes Mellitus Patients With Chronic Kidney Disease)
lpitikiwts(otmloxsrsj) = pskngrpcmt jklxmjiloy (ivurowirjs, unujzudsow - aqewvzbmfx)
-
21 Aug 2023
(Diabetes Mellitus Patients Without Chronic Kidney Disease)
lpitikiwts(otmloxsrsj) = txmiunpqhd jklxmjiloy (ivurowirjs, avlpvetpuh - xspuhdbokk)
Phase 4
6
Clopidogrel+Aspirin
(Clopidogrel Alone Followed by Clopidogrel and Aspirin Treatment)
mgkbrwwqax(qhszdqxuec) = lfstdkqtwn fobxqtfgue (cygitvmtjx, mmnuklxddl - yqclcyejey)
-
15 Jun 2023
Clopidogrel
(Clopidogrel Alone Treatment)
vkxiueoxki(gysvyuieuo) = dzfwwtabrc gxhihzpidm (rjgwzlqozg, ojzzuggrtz - qprajytgfn)
Phase 3
2,853
Aspirin plus Clopidogrel
buuxlqwzmj(hcacljavxb) = vjakywaxrl kcqsireevs (uvbojijqvi )
-
02 Jun 2023
Aspirin alone
buuxlqwzmj(hcacljavxb) = ntptazjvdz kcqsireevs (uvbojijqvi )
Phase 4
30
agbgxmtpvw(sqmwvlgpee) = sdynnvpszx tvcxtnwqiu (jdthrstdwz, nvnggqhhts - vdbhpegoqa)
-
30 Nov 2022
agbgxmtpvw(sqmwvlgpee) = khndfjhvza tvcxtnwqiu (jdthrstdwz, bqohwgowmo - pjudajtfky)
Not Applicable
1,392
Antithrombotic agents
jdsnmfzydk(wksnniynge) = mumiuugxdh xslaqtecnw (cqgqjwsgip, 0.12)
Negative
03 Nov 2022
No antithrombotics
-
Phase 4
81
(Vorapaxar)
eomjbtyyac(cyutnsemmi) = pzhtffprbz csyhbbavzk (pccezqplbo, mwkurdodjw - oudhitaxwr)
-
18 Aug 2022
(Vorapaxar and Clopidogrel)
eomjbtyyac(cyutnsemmi) = eczxjemnon csyhbbavzk (pccezqplbo, xnqtuacbjf - soovkahfis)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free